MediciNova US patent for method of treating progressive MS

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

MediciNova US patent for method of treating progressive MS

Postby MSUK » Mon Feb 06, 2012 2:55 am

Image


MediciNova Inc, a biopharmaceutical company, has received a Notice of Allowance from the US Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis.

Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.

A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1311
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2121
Joined: Wed Oct 14, 2009 3:00 pm

Re: MediciNova US patent for method of treating progressive

Postby NHE » Mon Feb 06, 2012 4:42 am

More info on ibudilast from MediciNova...

http://www.medicinova.com/html/research ... etoverview

also...

http://www.chemicalbook.com/ProductChem ... 945_EN.htm

Phosphodiesterase inhibitor (IC 50 values are 53, 35, 48, 12 and 10 mM for PDE Ia, II, III, IV and V respectively). Inhibits platelet aggregation and is an orally-active cerebral vasodilator, bronchodilator and antiallergic agent.


also...

About 111 articles on ibudilast listed on Pubmed (should make for some interesting reading).

http://www.ncbi.nlm.nih.gov/pubmed?term=ibudilast


NHE
User avatar
NHE
Volunteer Moderator
 
Posts: 3300
Joined: Sat Nov 20, 2004 4:00 pm


Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service